XML 26 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Instruments
6 Months Ended
Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments Derivative Instruments

The Company may enter into foreign currency forward or option contracts (derivative contracts) to manage foreign currency risk on expected cash flows and certain existing assets and liabilities, primarily intercompany balances. Certain of these derivative contracts are designated as cash flow hedges of forecasted sales (Designated Derivative Contracts). The Company may also enter into derivative contracts that are not designated as cash flow hedges (Non-Designated Derivative Contracts), to offset a portion of anticipated gains and losses on certain intercompany balances until the expected time of repayment.

The after-tax unrealized gains or losses from changes in the fair value of Designated Derivative Contracts are recorded as a component of accumulated other comprehensive loss (AOCL) and are reclassified to net sales in the condensed consolidated statements of comprehensive income in the same period or periods as the related sales are recognized. The Company includes all hedge components in its assessment of effectiveness for its derivative contracts.

Changes in the fair value of Non-Designated Derivative Contracts are recorded in SG&A expenses in the condensed consolidated statements of comprehensive income. The changes in fair value for these contracts are generally offset by the remeasurement gains or losses associated with the underlying foreign currency-denominated intercompany balances, which are recorded in SG&A expenses in the condensed consolidated statements of comprehensive income.

As of September 30, 2020, the Company had the following derivative contracts recorded at fair value in the condensed consolidated balance sheets:
 
Designated
Derivative Contracts
 
Non-Designated Derivative Contracts
 
Total
Notional value
$
53,444

 
$
18,909

 
$
72,353

Fair value recorded in other current assets
243

 
42

 
285

Fair value recorded in other accrued expenses
831

 

 
831



As of September 30, 2020, the Company's outstanding derivative contracts were held by an aggregate of four counterparties, all with various maturity dates within the next six months. As of March 31, 2020, the Company had no outstanding derivative contracts.

The following table summarizes the effect of Designated Derivative Contracts and the related income tax effects for unrealized gains or losses recorded in the condensed consolidated statements of comprehensive income for changes in AOCL:
 
Three Months Ended September 30,
 
Six Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
(Loss) gain recorded in OCI
$
(1,173
)
 
$
2,190

 
$
(709
)
 
$
1,773

Reclassifications from AOCL into net sales
121

 
(216
)
 
121

 
(216
)
Income tax benefit (expense) in OCI
252

 
(477
)
 
141

 
(377
)
Total
$
(800
)
 
$
1,497

 
$
(447
)
 
$
1,180



The following table summarizes the effect of Non-Designated Derivative Contracts:
 
Three Months Ended September 30,
 
Six Months Ended September 30,
 
2020
 
2019
 
2020
 
2019
Gain recorded in SG&A expenses
$
42

 
$
502

 
$
42

 
$
146



The non-performance risk of the Company and the counterparties did not have a material impact on the fair value of its derivative contracts. As of September 30, 2020, the amount of unrealized losses on derivative contracts recorded in AOCL is expected to be reclassified into net sales within the next six months. Refer to Note 10, “Stockholders' Equity,” for further information on the components of AOCL.